Long-term therapy with rifampin and the secondary antibody response to killed influenza vaccine.
The secondary antibody response was studied in 22 patients with tuberculosis, 11 of whom were taking rifampin as part of their antituberculous regimen. The mean duration of rifampin therapy was 12.7 months. Hemagglutination-inhibiting antibody titers to bivalent influenza vaccine were determined before, and 4 and 8 weeks after, vaccination. There was no significant difference in the number of patients who developed a 4-fold or greater increase in titer, or in the level of titer response between the rifampin and control groups. Long-term therapy with rifampin was not found to suppress the secondary antibody response to influenza vaccination.
D000914:Antibodies, Viral / Q000032:analysis*; D006801:Humans; D007165:Immunosuppression Therapy; D007252:Influenza Vaccines; D012293:Rifampin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy / Q000276:immunology*
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D012293:Rifampin